Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes
But A Comeback Remains Possible
Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.
You may also be interested in...
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions
Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.